FDA Approves FoundationOne®CDx as a Companion Diagnostic in Melanoma

On December 8, 2021, the U.S. Food and Drug Administration (FDA) approved FoundationOne^®CDx to be used as a companion diagnostic for two groups of current and future FDA-approved therapeutics in melanoma, which includes BRAF inhibitor monotherapies targeting BRAFV600E and BRAF/MEK inhibitor combination therapies targeting BRAFV600E or V600K mutations. 

Read the Foundation Medicine announcement.

Posted 12/8/2021